Clinical Trial: A Phase 1 Study of IM-1021 in Participants with Advanced Cancer

U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06823167) titled 'A Phase 1 Study of IM-1021 in Participants with Advanced Cancer' on Feb. 04.

Brief Summary: IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: Solid Malignancies Hematologic Malignancies

Intervention: BIOLOGICAL: IM-1021

IM-1021 is an antibody-drug conjugate

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Immunome, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....